<DOC>
	<DOCNO>NCT01150760</DOCNO>
	<brief_summary>Alvimopan first currently FDA-approved therapy acceleration time upper low gastrointestinal ( GI ) recovery follow partial large small bowel resection surgery primary anastomosis . The primary objective retrospective observational trial ass postoperative morbidity mortality report index hospitalization bowel resection 15/30-day readmission alvimopan vs. non-alvimopan matched patient combine Premier/Care Science database ( large medical claim database ) .</brief_summary>
	<brief_title>Clinical Outcomes After Bowel Resection Patients Receiving Alvimopan Versus Patients Not Receiving Alvimopan Premier Perspective Database</brief_title>
	<detailed_description />
	<mesh_term>Alvimopan</mesh_term>
	<criteria>â‰¥ 18 year discharge Medical claim ICD9CM procedure code primary procedure ( identify position 1 2 involve large small segmental bowel resection primary anastomosis Discharged within study date Surgery participate Premier/Care Sciences hospital Had divert ostomy without primary anastomosis index hospitalization Had trauma diagnosis Had bowel resection perform 1 day index hospitalization ( include case bowel resection intestinal anastomosis perform different day index hospitalization ) Had exclude nonbowel resection surgical code ( i.e. , code major nonBR surgical procedure [ eg. , nephroureterectomy , total joint replacement ] position 1 2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>GI recovery bowel resection</keyword>
	<keyword>morbidity bowel resection</keyword>
	<keyword>mortality</keyword>
	<keyword>readmission</keyword>
	<keyword>length stay</keyword>
</DOC>